Selectivity switching between CO and formate for CO_(2) reduction on Sb modified amorphous ZnO by electronic effect

The adjustable intermediate binding capacity in electrocatalytic carbon dioxide(CO_(2))reduction is critical for varying the reaction pathways to desired products.Herein,we first report the synthesis of boron-doped amorphous zinc oxide with(B-a-ZnO-Sb)or without antimony nanoparticles embedding(B-a-ZnO)via one-step wet chemical method,which is easy to scale up by enlarging the vessel and increasing feeding.Sb successfully realizes the product switching from CO on B-a-ZnO to formate on B-a-ZnOSb.Both experimental and theoretical results reveal that Sb weakens the charge interaction on Zn atoms.Based on the moderate adsorption of*COOH and strong adsorption of*OCHO and*HCOOH for B-a-ZnO,the foreign Sb weakens the adsorption of these intermediates and brings about a favor formate production instead of CO.This work points out a new direction for the synthesis of amorphous ZnO-based catalysts and provides advanced insights into the aimed selectivity switch for CO_(2)reduction by electronic effect.

Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular carcinoma

Biomarkers for hepatocellular carcinoma (HCC) following curative resection are not currently sufficient for prognostic indication of overall survival (OS) and disease-free survival (DFS). The aim of this study was to investigate the prognostic performance of osteopontin (OPN), matrix metalloproteinase 7 (MMP7), and pregnancy specific glycoprotein 9 (PSG9) in patients with HCC. A total of 179 prospective patients with HCC provided plasma before hepatectomy. Plasma OPN, MMP7, and PSG9 levels were determined by enzyme-linked immunosorbent assay. Correlations between plasma levels, clinical parameters, and outcomes (OS and DFS) were overall analyzed. High OPN (≥149.97 ng/mL), MMP7 (≥2.28 ng/mL), and PSG9 (≥45.59 ng/mL) were prognostic indicators of reduced OS (P<0.001, P<0.001, and P=0.007, respectively). Plasma PSG9 protein level was an independent factor in predicting OS (P=0.008) and DFS (P=0.038). Plasma OPN+MMP7+PSG9 elevation in combination was a prognostic factor for OS (P<0.001). OPN was demonstrated to be a risk factor-associated OS in stage I patients with HCC and patients with low α-fetoprotein levels (<20 ng/mL). These findings suggested that OPN, MMP7, PSG9 and their combined panels may be useful for aiding in tumor recurrence and mortality risk prediction of patients with HCC, particularly in the early stage of HCC carcinogenesis.